Literature DB >> 18776163

Histopathology of vascular injury in Sprague-Dawley rats treated with phosphodiesterase IV inhibitor SCH 351591 or SCH 534385.

Jun Zhang1, Ronald D Snyder, Eugene H Herman, Alan Knapton, Ronald Honchel, Terry Miller, Parvaneh Espandiari, Federico M Goodsaid, Irwin Y Rosenblum, Joseph P Hanig, Frank D Sistare, James L Weaver.   

Abstract

Histopathological and immunohistochemical studies were conducted to characterize vascular injuries in rats treated with phosphodiesterase (PDE) IV inhibitors SCH 351591 or SCH 534385. Sprague-Dawley rats were administered PDE IV inhibitors by gavage at a range of doses and times. The two PDE IV inhibitors induced comparable levels of vascular injury, primarily in the mesentery and to a lesser extent in the pancreas, kidney, liver, small intestine, and stomach. Mesenteric vascular changes occurred as early as one hour, progressively developed over twenty-four to forty-eight hours, peaked at seventy-two hours, and gradually subsided from seven to nine days. The typical morphology of the vascular toxicity consisted of hemorrhage and necrosis of arterioles and arteries, microvascular injury, fibrin deposition, and perivascular inflammation of a variety of blood vessels. The incidence and severity of mesenteric vascular injury increased in a time- and dose-dependent manner in SCH 351591- or SCH 534385-treated rats. Mesenteric vascular injury was frequently associated with activation of mast cells (MC), endothelial cells (EC), and macrophages (MØ). Immunohistochemical studies showed increases in CD63 immunoreactivity of mesenteric MC and in nitrotyrosine immunoreactivity of mesenteric EC and MØ. The present study also provides a morphological and cellular basis for evaluating candidate biomarkers of drug-induced vascular injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18776163     DOI: 10.1177/0192623308322308

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  4 in total

1.  Postinjury treatment with rolipram increases hemorrhage after traumatic brain injury.

Authors:  C M Atkins; Y Kang; C Furones; J S Truettner; O F Alonso; W D Dietrich
Journal:  J Neurosci Res       Date:  2012-04-26       Impact factor: 4.164

2.  Proceedings of the 2014 National Toxicology Program Satellite Symposium.

Authors:  Susan A Elmore; Michelle C Cora; Margarita M Gruebbel; Schantel A Hayes; Jessica S Hoane; Haruko Koizumi; Rachel Peters; Thomas J Rosol; Bhanu P Singh; Kathleen A Szabo
Journal:  Toxicol Pathol       Date:  2014-11-09       Impact factor: 1.902

3.  Effects of early rolipram treatment on histopathological outcome after controlled cortical impact injury in mice.

Authors:  Coleen M Atkins; Maria L Cepero; Yuan Kang; Daniel J Liebl; W Dalton Dietrich
Journal:  Neurosci Lett       Date:  2012-10-26       Impact factor: 3.046

4.  Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.

Authors:  Alex B Burgin; Olafur T Magnusson; Jasbir Singh; Pam Witte; Bart L Staker; Jon M Bjornsson; Margret Thorsteinsdottir; Sigrun Hrafnsdottir; Timothy Hagen; Alex S Kiselyov; Lance J Stewart; Mark E Gurney
Journal:  Nat Biotechnol       Date:  2009-12-27       Impact factor: 54.908

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.